Carla I Falkson

Prof. Dr. Carla I Falkson

James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, NY, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NNNiraj Neupane
Niraj Neupane
SBSawyer Bawek
Sawyer Bawek
SGSayuri Gurusinghe
Sayuri Gurusinghe
EGElham Moases Ghaffary
Elham Moases Ghaffary
OMOmid Mirmosayyeb
Omid Mirmosayyeb
ADAjay Dhakal
Ajay Dhakal
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients. Second-generation SERDs were developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives.

29 April 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
ACAmy S. Clark
Amy S. Clark
FZFengmin Zhao
Fengmin Zhao
PKPaula Klein
Paula Klein
Alberto J MonteroAlberto J Montero
Alberto J Montero
CFCarla I Falkson
Carla I Falkson
KMKathy D. Miller
Kathy D. Miller
Purpose: Pelareorep (Pel) is a type 3 oncolytic reovirus that upregulates PD-L1 expression. We determined the objective response rate (ORR) with paclitaxel (Pac), Pac + Pel, or Pac + Pel + avelumab (Ave). Patients and Methods: Patients with hormone receptor–positive, HER2-negative metastatic breast cancer who had progressed on at least one line of endocrine therapy with a cyclin-dependent kinase 4/6 inhibitor and had not received chemotherapy for metastatic breast cancer were eligible. Patients were randomized 1:1:1 to Pac, Pac/Pel, or Pac/Pel/Ave after a three-patient run-in confirmed safety of the triplet regimen. Response was assessed every 8 weeks until week 16 and then every 12 weeks using RECIST v1.1. The primary endpoint was 16-week ORR. Statistical comparison across arms was not planned. Results: Forty-eight patients were enrolled, with 45 randomized. The 16-week ORR was 20%, 31%, and 14% in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. The median progression-free survival was 6.4, 12.1, and 5.8 months in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. There were more adverse events, particularly infusion reactions, in the combination arms than the Pac arm. Expansion of peripheral T-cell clones was observed by cycle 4 in Pac/Pel but not the Pac or Pac/Pel/Ave arms. Conclusions: The addition of Pel to Pac was associated with increased toxicity, expanded peripheral T-cell clones, and numerically increased the ORR and progression-free survival compared with Pac; Pac/Pel/Ave further increased toxicity and blunted T-cell responses without obvious increase in efficacy. Investigation of the Pac/Pel combination warrants consideration with careful attention to acute toxicity.

1 February 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PPParvin F. Peddi
Parvin F. Peddi
Peter FaschingPeter Fasching
Peter Fasching
DLDuan Liu
Duan Liu
EQEmmanuel Quinaux
Emmanuel Quinaux
NRNicholas J. Robert
Nicholas J. Robert
SHSara A. Hurvitz
Sara A. Hurvitz
Purpose: Cardiac toxicity is a serious potential complication of HER2-directed therapies and anthracyclines. HER2 codon 655 and SLC28A3 gene polymorphisms have been reported to be associated with cardiac toxicity from anti-HER2 and anthracycline therapy, respectively. Association of the polymorphism at HER2 codon 655 with prognosis has also been reported. Experimental Design: Whole blood samples from patients treated on a randomized adjuvant breast cancer trial (BCIRG-006) that compared chemotherapy with or without trastuzumab plus either anthracycline or nonanthracycline chemotherapy were tested for genetic polymorphisms in HER2 codon 655 and SLC28A3. Genotypes were correlated with cardiac function and disease-free survival (DFS) outcomes. Results: Of 3,222 patients enrolled in BCIRG-006, 662 patient samples were successfully genotyped for the rs1136201 allele in HER2 (codon 655): 424 (64%) were AA, 30 (4.5%) were GG, and 208 (31%) were AG genotype. In addition, 665 patient samples were successfully genotyped for the rs7853758 allele in the SLC28A3 gene: 19 (3%) were AA, 475 (71%) were GG, and 171 (26%) were AG genotype. Follow-up time was 10 years. No correlation between DFS, cardiac event rate, or mean left ventricular ejection fraction (LVEF) and rs1136201 genotype was seen in the trastuzumab-treated or non–trastuzumab-treated patients. Moreover, mean LVEF and cardiac event rates were similar in all rs7853758 genotype groups treated with anthracycline-based therapy. Conclusions: In the largest study to date to evaluate whether two polymorphisms are associated with DFS and/or cardiac toxicity in HER2-positive breast cancer treated with trastuzumab and/or anthracyclines, we observed no correlation.

1 January 1996 in Oncology
Verified
Journal Article
Closed access
PDF file
CFCarla I Falkson
Carla I Falkson
HFHendre C. Falkson
Hendre C. Falkson
GFGeoffrey Falkson
Geoffrey Falkson
Thirty-four patients with histologically confirmed ovarian cancer were entered into a pilot study. Patients were randomized to receive cisplatin alone or cisplatin plus D-Trp-6-LHRH (decapeptyl). Objective response (complete and partial response) was documented in 9 of 14 patients on cisplatin and in 12 of 18 patients on cisplatin plus decapeptyl. Median time to treatment failure and median survival times were the same in the two treatment regimens. Toxicities were similar in the two treatment arms, except for hot flashes which only occurred in patients on cisplatin plus decapeptyl.

20 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CFCarla I Falkson
Carla I Falkson
JRJ. F. Rossman
J. F. Rossman
LNL. Nabell
L. Nabell
JCJ. Carpenter
J. Carpenter
MSM. N. Saleh
M. N. Saleh
AFA. Forero
A. Forero
1074 Background: Metastatic breast cancer (MBC) remains the second most common cause of cancer death in women in the US. In hormone responsive disease, patients have demonstrated prolonged survival with few side effects, but eventually the cancer becomes resistant to hormone therapy, and cytotoxic chemotherapy with increased toxicity is required. Our Breast Cancer SPORE discovered that increased expression of VEGF caused acquired tamoxifen resistance and tumor loss of estrogen dependence in MCF-7 xenografts. VEGF over- expressing MCF-7 cells displayed increased tumor growth rates and estrogen independence in vivo, and reversal of VEGF over-expression in vivo returned tumors to estrogen dependent growth. Methods: We hypothesized that adding the anti-VEGF monoclonal antibody, bevacizumab, to hormonal therapy would result in reversal of acquired hormone resistance. This multi-center, open-label, single arm phase II study was designed to evaluate safety and efficacy of this combination. Primary endpoint was time to progression (TTP), and the secondary endpoints were response rate and toxicity. Eligible patients had MBC and had progressed on hormonal therapy after previously responding for at least 6 months. Results: Planned interim analysis results are reported here. All 19 patients were female with median age of 63 years, and all had ER and/or PR positive MBC. Patients were continued on the same hormone therapy to which they had become refractory, and bevacizumab (15mg/kg IV every 3 weeks) was added. Treatment was stopped early in 3 patients due to a grade 3 leg ulcer, grade 3 hypertension, and grade 3 fatigue, respectively. Overall, the therapy was tolerated well, and no treatment-related deaths or thromboembolic events were seen. Stable disease was documented in 11 (58%) patients, and mean TTP in these patients was 5.8 months (range 1.5 - 12+). There were no complete or partial responses, and 8 (42%) had progression of disease. Conclusions: Our data suggest that it is safe to combine bevacizumab with hormone therapy in MBC, and this intervention may prolong the TTP without adding adverse side effects. Further investigation utilizing this combination in MBC is warranted.